The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Brain metastases affect a significant percentage of patients with advanced extracranial
malignancies. Yet, the incidence of brain metastases remains poorly described, largely due …

Purpose To provide guidance to clinicians regarding therapy for patients with brain
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …

Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Low grade gliomas are the most frequent brain tumors in children and encompass a
spectrum of histologic entities which are currently assigned World Health Organisation …

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase
(ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the …

Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)–
rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience …